EVAX Total Utang marang Modal Evaxion Biotech A/S

Evaxion Biotech A/S (EVAX) is actively developing personalized oncology treatments by utilizing the PIONEER system to analyze specific mutations. Business growth is driven by partnerships with pharmaceutical behemoths and the success of clinical trials. The linear price action on the GURU.Markets chart shows that the individual debt-to-equity ratio is 0.81. Due to the technological superiority of EDIVAX, the company possesses significant pricing power in setting the cost of its products.

Evaxion Biotech - Utang marang Modal EVAX (periode 04.07.2022 - 28.10.2026)

Rincian analitis perusahaan Evaxion Biotech A/S

- rega lan prakiraan konsensus rega:

Rega saham Evaxion|EVAX - Prakiraan konsensus analis

- data kapitalisasi pasar:

Kapitalisasi pasar Evaxion|EVAX - Rega Tumbas Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Evaxion|EVAX - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih evaxion-biotech.com|EVAX - Aset Agregat Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Evaxion Biotech A/S|EVAX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Evaxion Biotech A/S|EVAX - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Evaxion|EVAX - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Evaxion

Analisis dhasar perusahaan:Evaxion - EVAX

This ratio measures financial leverage by comparing total liabilities to net assets to determine the business's degree of dependence on debt financing. By analyzing the proportion of total debt to equity, an investor can assess the resilience of Evaxion Biotech A/S (EVAX) to geopolitical risks and trade restrictions, which could limit revenue from international software and complicate debt servicing.

Pesaing wigati